ePrivacy and GPDR Cookie Consent by Cookie Consent

Durvalumab With or Without Tremelimumab for Patients With Metastatic Pancreatic Ductal Adenocarcinoma


Oct. 21, 2019


Another disappointing clinical trial outcome, with the immunotherapy combo durvalumab plus tremelimumab (aPDL1 + aCTLA4) failing to produce a benefit in advanced disease (ORR 3% for combination).

Treatment was well tolerated, and the efficacy of durvalumab plus tremelimumab therapy and durvalumab monotherapy reflected a population of patients with mPDAC who had poor prognoses and rapidly progressing disease. Patients were not enrolled in part B because the threshold for efficacy was not met in part A.